Pharmaceutical composition with synergistic effect for treating cancer metastasis as well as preparation method and application of pharmaceutical composition
Through the synergistic effect of abecili and curcumin, the formation of co-carrying liposomes has been solved in the prior art side effects and poor effects in treating cancer metastasis, significantly inhibit cancer metastasis and improve immunosuppressive TME, enhancing immunity reaction.
Patent Information
- Application Number
- CN202411004568.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-08
AI Technical Summary
Prior Art Abecili (ABE) may cause adverse side effects when treating cancer metastasis and targeting effector T cells alone is not sufficient to comprehensively improve the immunosuppressive tumor microenvironment (TME), while curcumin (Cur) is used alone It is also difficult to completely inhibit tumor-promoting factors.
Combining abecili (ABE) with curcumin (Cur) to form a synergistic pharmaceutical composition, which increases the number of effector T cells by improving immunosuppressive TME, inhibits Treg cell proliferation and interleukin-1, transformation The content of tumor-promoting factors such as growth factor-β, hypoxia-inducible factor-1 and vascular endothelial growth factor was prepared as abecili-curcumin co-loading liposomes, and was prepared by thin-film dispersion method and pH gradient active drug-loading method.
Significantly inhibit the development of cancer metastasis, enhance immune response, reduce non-specific damage to the body by drugs, and improve treatment effect.
Smart Images

Figure CN118903140A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and relates to a synergistic pharmaceutical composition for treating cancer metastasis, a preparation method and an application thereof, and specifically, a synergistic pharmaceutical composition for treating cancer metastasis by improving an immunosuppressive tumor microenvironment (TME) and an application thereof. The pharmaceutical composition increases the number of effector T cells through the synergistic effect between drugs, and inhibits the proliferation of regulatory T (Treg) cells and the content of tumor-promoting factors such as interleukin-1 (IL-1), transforming growth factor-β (TGF-β), hypoxia-inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF) in the TME, thereby improving the immunosuppressive TME and treating cancer metastasis. Background Art
[0002] Cancer metastasis refers to the process by which tumor cells spread to distant organs, form metastatic nodules, and invade tissues. Metastasis is a major factor leading to cancer-related deaths. Therefore, early detection and treatment of cancer metastasis is crucial. With the development of nanotechnology, some nanodrug delivery systems (NDDS) have emerged to improve the physicochemical properties of drugs, thereby more accurately and efficiently detecting and treating cancer metastasis. By targeted delivery to tumor cells, diagnostic and therapeutic drugs can be highly concentrated at the site of cancer metastasis.
[0003] Before tumor cells infiltrate the metastatic site, distant organs need to prepare an environment that is conducive to the survival and growth of tumor cells, namely the pre-metastatic niche (PMN). Among them, neutrophils are the first immune cells recruited into PMNs, with the largest number, accounting for more than 70% of the total number of recruited cells. Neutrophils promote the final formation of metastases by supporting tumor cell proliferation, stimulating angiogenesis, and creating an immunosuppressive environment. Therefore, compared with treatment strategies targeting tumor cells, NDDS targeting neutrophils has the potential to detect metastases earlier. In addition, by regulating the pro-metastatic mechanism of neutrophils, an integrated approach to the diagnosis and treatment of tumor metastasis can be achieved.
[0004] Abemaciclib (ABE), a CDK4 / 6 inhibitor, has been approved for clinical treatment of breast cancer. It has the ability to inhibit regulatory T (Treg) cell proliferation and enhance effector T cell activity, thereby regulating the immunosuppressive microenvironment (TME) formed by pro-metastatic neutrophils. However, the use of ABE in the clinic may lead to adverse side effects and limited effectiveness. In addition, targeting effector T cells and Treg cells alone is not sufficient to achieve a comprehensive improvement in the immunosuppressive environment. Therefore, ABE is considered to be used in combination with curcumin (Cur). Cur has been shown to be able to hinder the transformation, proliferation and metastasis of tumor cells while inducing apoptotic pathways. In addition, Cur has been observed to inhibit the release of tumorigenic factors from pro-metastatic neutrophils, including interleukin-1 (IL-1), transforming growth factor-β (TGF-β), hypoxia-inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF), thereby comprehensively improving the immunosuppressive TME of cancer metastases. Summary of the invention
[0005] The purpose of the present invention is to provide a synergistic pharmaceutical composition for treating cancer metastasis in view of the deficiencies of the prior art, which can increase the number of effector T cells and inhibit the proliferation of regulatory T (Treg) cells and the content of tumor-promoting factors such as interleukin-1 (IL-1), transforming growth factor-β (TGF-β), hypoxia-inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF) in the immunosuppressive tumor microenvironment (TME), thereby improving the immunosuppressive TME and treating cancer metastasis.
[0006] The technical solution adopted by the present invention is:
[0007] A synergistic pharmaceutical composition for treating cancer metastasis is composed of abemaciclib ABE and curcumin Cur, wherein the mass concentration ratio of ABE to Cur is 1:500 to 500:1.
[0008] Preferably, in the above-mentioned pharmaceutical composition, the mass concentration ratio of ABE and Cur is 1:1.
[0009] Furthermore, the above-mentioned pharmaceutical composition and pharmaceutically acceptable carrier can be prepared into a clinically acceptable preparation, which is an injection, an oral preparation or an external preparation.
[0010] Preferably, the above-mentioned pharmaceutical composition is abemaciclib-curcumin co-loaded liposomes, and the liposomes are prepared by a thin film dispersion method and loaded with drugs by a pH gradient active drug loading method.
[0011] Furthermore, the preparation method of the above-mentioned abemaciclib-curcumin co-loaded liposomes comprises the following steps:
[0012] 1) Preparation of liposomes by thin film dispersion method: accurately weighed phospholipid S100, cholesterol CH and Cur were dissolved in a round-bottom flask with chloroform, and the solvent was removed by rotary evaporator to form a thin lipid film; then hydrated in preheated citric acid buffer at 65°C for 20 minutes, and the mixture was sonicated for 8 minutes using a probe sonicator to obtain liposomes; the liposomes were filtered through a polycarbonate membrane in sequence to remove large particles, and finally Cur@CL was formed;
[0013] 2) ABE was loaded into liposomes by using a pH gradient active drug loading method: sodium phosphate solution was mixed with the Cur@CL suspension prepared in step 1) to establish a pH gradient; abemaciclib hydrochloride solution was added to Cur@CL, and then treated at 60°C for 20 minutes; unloaded abemaciclib hydrochloride was removed using a cation exchange resin, thereby preparing ABE / Cur@CL.
[0014] Furthermore, in the method for preparing the above-mentioned abemaciclib-curcumin co-loaded liposomes, in step 1), the mass ratio is S100:CH:Cur=10:4:1.
[0015] Furthermore, in the preparation method of the above-mentioned abemaciclib-curcumin co-loaded liposomes, the mass ratio is S100:ABE=10:1.
[0016] Furthermore, in the above-mentioned method for preparing abemaciclib-curcumin co-loaded liposomes, in step 2), the concentration of the sodium phosphate solution is 0.5M.
[0017] Use of any of the above-mentioned pharmaceutical compositions in the preparation of drugs for treating cancer metastasis.
[0018] The pharmaceutical composition described in any of the above items is used in drugs for treating cancer metastasis by increasing the number of effector T cells, inhibiting the proliferation of Treg cells in TME and the content of interleukin-1, transforming growth factor-β, hypoxia-inducible factor-1 and vascular endothelial growth factor tumor-promoting factors, thereby improving the immunosuppressive TME.
[0019] Furthermore, in any of the above applications, the cancer is breast cancer, and the cancer metastasis is lung metastasis.
[0020] The beneficial effects of the present invention are:
[0021] 1. By using the pharmaceutical composition of the present invention, the synergistic effect of the two drugs is exerted to significantly inhibit the development of cancer metastasis.
[0022] 2. The co-loaded liposomes prepared by the present invention do not cause non-specific damage to the body. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1This is the transmission electron microscopy image of ABE / Cur@CL.
[0024] Figure 2 It is the in vitro release curve of ABE in ABE / Cur@CL.
[0025] Figure 3 It is the in vitro release curve of Cur in ABE / Cur@CL.
[0026] Figure 4 These are the flow cytometry results of ABE-S, Cur-S, ABE / Cur-S, ABE@CL, Cur@CL, and ABE / Cur@CL.
[0027] Figure 5 It is the ELISA result graph of ABE-S, Cur-S, ABE / Cur-S, ABE@CL, Cur@CL, and ABE / Cur@CL. DETAILED DESCRIPTION
[0028] Example 1 Abemaciclib-Curcumin Co-loaded Liposomes (ABE / Cur@CL)
[0029] (I) The preparation method is as follows:
[0030] 1. Preparation of Cur@CL
[0031] 1) Accurately weigh 100 mg S100, 40 mg CH, and 10 mg Cur into a round-bottom flask, add 5 mL chloroform to dissolve the above samples, and remove the solvent using a rotary evaporator to form a thin lipid film.
[0032] 2) Then hydrate in preheated citric acid buffer (200 mmol / L) at 65°C for 20 minutes.
[0033] 3) The mixture was sonicated for 8 minutes (200 W×2 minutes, 400 W×6 minutes) using a probe sonicator to obtain liposomes.
[0034] 4) The liposomes were filtered through polycarbonate membranes (0.8, 0.45, and 0.22 μm) in sequence to remove large particles and finally form Cur@CL.
[0035] 2. Preparation of ABE / Cur@CL
[0036] 1) Take 1 mL of Cur@CL and add 400 μL of sodium phosphate solution (0.5 M) to adjust the pH of the external aqueous phase to 7.0 to obtain pH gradient liposomes.
[0037] 2) The gradient liposomes were mixed with abemaciclib hydrochloride solution (4 mg / mL, 500 μL) and stirred in a 60°C water bath for 20 minutes.
[0038] 3) The unloaded abemaciclib hydrochloride was removed by cation exchange resin to prepare ABE / Cur@CL.
[0039] (II) Detection and characterization
[0040] 1. Particle size and Zeta potential determination
[0041] Take an appropriate amount of sample, dilute with sterile water for injection and transfer to the sample pool, use Nano-zs 90 dynamic light scattering particle size analyzer at 632.8nm wavelength to measure the particle size and polydispersity coefficient of the preparation, and operate each sample in parallel 3 times to obtain the particle size, Zeta potential and PDI value of the sample. The results are shown in Table 1. The particle size of the prepared ABE / Cur@CL is about 120nm, and the particle size distribution is relatively uniform. The Zeta potential is about -20mV.
[0042] 2. Determination of ABE and Cur encapsulation efficiency (EE%)
[0043] Accurately pipette 2 portions of prepared liposomes, 0.1 mL each, transfer one portion to a 10 mL volumetric flask, add 1.2 mL of sterile water for injection, dilute to scale with demulsifier methanol, mix well, and measure the total drug absorbance A0 at a wavelength of 480 nm. The other portion is placed on the top of the dextran gel column, centrifuged at 2000 rpm for 4 minutes, and then 400 μL of sterile water for injection is added to the top of the column, centrifuged at 2000 rpm for 4 minutes. This operation is repeated 3 times, the eluate is combined, transferred to a 10 mL volumetric flask, diluted to scale with demulsifier methanol, mixed well, and the absorbance values at 277 nm (ABE) and 425 nm (Cur) are measured with a UV / visible spectrophotometer. The encapsulated drug absorbance A1 is measured, and the encapsulation efficiency of ABE and Cur is calculated as follows: EE% = A1 / A0×100%. As shown in Table 1, the encapsulation rates of ABE and Cur in liposomes exceeded 80%, which can meet the requirements of subsequent in vitro and in vivo experiments.
[0044] Table 1 Characterization results of liposomes
[0045] index Size(nm) PDI Zeta(mV) EE%(ABE) EE%(CUR) ABE / Cur@CL 126.3±2.0 0.189±0.002 -19.2±0.7 83.6±1.2 88.3±1.0
[0046] Note: Data are expressed as mean ± standard deviation (n = 3).
[0047] 3. Transmission electron microscope (TEM) test
[0048] The morphology and particle size distribution of liposomes were observed using a transmission electron microscope. A small amount of diluted sample was dripped onto a 230-mesh copper grid, stained with 2% phosphotungstic acid solution, excess liquid was removed, the sample was naturally air-dried, and then photographed under a transmission electron microscope. Figure 1As shown, the prepared liposomes all have a double-layer spherical vesicle structure and are uniform in size, which is basically consistent with the data measured by the particle size analyzer.
[0049] 4. Investigation of in vitro release behavior
[0050] Accurately pipette 1.0 mL of each of ABE solution (ABE-S), Cur solution (Cur-S), ABE / Cur mixed solution (ABE / Cur-S), ABE ordinary liposomes (ABE@CL), Cur ordinary liposomes (Cur@CL), and ABE / Cur co-loaded liposomes (ABE / Cur@CL) into a dialysis bag (molecular weight cutoff 10 kDa), clamp both ends and place in 100 mL of PBS release medium, and stir at 100 rpm in the dark at 37°C. Collect 1.0 mL of dialysate at 0.5, 1, 2, 4, 8, 12, and 24 h, and add an equal amount of fresh release medium. Filter the dialysate with a 0.22 μm microporous filter membrane, and detect the concentrations of ABE and Cur in the filtrate with a UV / visible spectrophotometer, and calculate the cumulative release of the drug. The results are shown in Figure 2. Figure 2 and Figure 3 As shown, within 24 h, the cumulative release rates of ABE and Cur in different liposome preparations were less than 30%.
[0051] Example 2 Cell activity test
[0052] Five concentration gradients were set for both the ABE group and the Cur group. ABE-S group: 0.1, 1, 5, 10 and 50 μg / mL; Cur-S group: 0.1, 1, 5, 10 and 50 μg / mL; the concentrations of ABE and Cur in the ABE / Cur-S group were the combination of the concentrations in the ABE-S group and the Cur-S group. 4T1 cells in the logarithmic growth phase (1×10 cells / well) were added to a 96-well plate. 5 ) and placed it in a cell culture incubator overnight. (37°C, 5% CO2). The next day, a series of prepared concentration gradient drugs were added to a 96-well plate, with 3 replicate wells for each concentration. After 48 hours, 20 μL of MTT (5 mg / mL) was added to each well and incubated at 37°C for 4 hours. The absorbance of each well at a wavelength of 490 nm was measured using an ELISA reader (800TS, Agilent, USA). The CI value was calculated by CompuSyn (Ashton, 2015). (CI<1: synergistic effect, the smaller the CI value, the stronger the synergistic effect; CI=1: additive effect; CI>1: antagonistic effect, the larger the CI value, the stronger the antagonistic effect). The results in Table 2 show that the CI value of the ABE / Cur-S group is less than 1, proving that ABE and Cur have a synergistic inhibitory effect on 4T1 cells.
[0053] Table 2 Non-constant ratio combination index of abemaciclib and curcumin on 4T1 cells
[0054]
[0055] Example 3 Flow cytometry
[0056] Female BALB / c mice were randomly divided into 7 different groups: control group, ABE-S group, Cur-S group, ABE / Cur-S group, ABE@CL group, Cur@CL group, and ABE / Cur@CL group. BALB / c mice were intravenously injected with 4T1 cells (1×10 5 ), and an experimental lung metastasis model was established in mice. The mice were treated with different preparations on days 4, 7, and 10. After 21 days, the mouse lungs were removed, cut into small pieces, and digested with 0.3% collagenase IV and 0.05% DNase I (Biyuntian) at 37°C with gentle shaking for 40 minutes. After filtering through a cell filter, all samples were purified using red blood cell lysis buffer to remove red blood cells. In order to study effector T cells (CD3 + CD4 - CD8 + )(CD3 + CD4 + CD8 - ), anti-CD3-FITC, anti-CD8-APC, and anti-CD4-PerCP antibodies were used for cell labeling. + CD4 + CD25 + Foxp3 + ), cells were labeled with anti-CD3-FITC, anti-CD4-PerCP, anti-CD25-APC, and anti-Foxp3-PE antibodies. Cells were permeabilized and fixed using staining buffer for Foxp3 intracellular staining. Figure 4 These results showed that ABE / Cur@CL could effectively inhibit the proliferation of Tregs and enhance the activity of effector T cells.
[0057] Example 4 ELISA experiment
[0058] Female BALB / c mice were randomly divided into 7 different groups: control group, ABE-S group, Cur-S group, ABE / Cur-S group, ABE@CL group, Cur@CL group, and ABE / Cur@CL group. BALB / c mice were intravenously injected with 4T1 cells (1×10 5The experimental lung metastasis model was established in mice. The mice were treated with different preparations on days 4, 7, and 10. After 21 days, the mouse lungs were removed, homogenized, and centrifuged. The levels of IL-1, TGF-β, HIF-1, and VEGF in the supernatant were quantified using an ELISA kit. The absorbance measurements were recorded at a wavelength of 450 nm using an ELISA reader. Figure 5 It showed that the levels of IL-1, TGF-β, HIF-1 and VEGF in the group receiving ABE / Cur@CL were lower than those in the other treatment groups.
Claims
1. A synergistic pharmaceutical composition for treating cancer metastasis, characterized in that: The pharmaceutical composition is composed of abemaciclib ABE and curcumin Cur, and the mass concentration ratio of ABE to Cur is 1:500 to 500:
1.
2. The pharmaceutical composition according to claim 1, characterized in that The mass concentration ratio of ABE and Cur is 1:
1.
3. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition and the pharmaceutically acceptable carrier can be prepared into a clinically acceptable preparation, which is an injection, an oral preparation or an external preparation.
4. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition is abemaciclib-curcumin co-loaded liposomes, and the liposomes are prepared by a thin film dispersion method and loaded with drugs by a pH gradient active drug loading method.
5. The pharmaceutical composition according to claim 4, characterized in that The preparation method of the abemaciclib-curcumin co-loaded liposome comprises the following steps: 1) Preparation of liposomes by thin film dispersion method: accurately weighed phospholipid S100, cholesterol CH and Cur were dissolved in a round-bottom flask with chloroform, and the solvent was removed by rotary evaporator to form a thin lipid film; then hydrated in preheated citric acid buffer at 65°C for 20 minutes, and the mixture was sonicated for 8 minutes using a probe sonicator to obtain liposomes; the liposomes were filtered through a polycarbonate membrane in sequence to remove large particles, and finally Cur@CL was formed; 2) ABE was loaded into liposomes by using a pH gradient active drug loading method: 0.5 M sodium phosphate solution was mixed with the Cur@CL suspension prepared in step 1) to establish a pH gradient; abemaciclib hydrochloride solution was added to Cur@CL, and then treated at 60°C for 20 minutes; ABE / Cur@CL was prepared by removing the unloaded abemaciclib hydrochloride using cation exchange resin.
6. The pharmaceutical composition according to claim 5, characterized in that In step 1), the mass ratio is S100:CH:Cur=10:4:
1.
7. The pharmaceutical composition according to claim 5, characterized in that In terms of mass ratio, S100:ABE=10:
1.
8. Use of the pharmaceutical composition according to any one of claims 1 to 7 in the preparation of a drug for treating cancer metastasis.
9. Use of the pharmaceutical composition of any one of claims 1-7 in a drug for treating cancer metastasis by increasing the number of effector T cells, inhibiting Treg cell proliferation and the content of interleukin-1, transforming growth factor-β, hypoxia-inducible factor-1 and vascular endothelial growth factor tumor-promoting factors in TME, thereby improving immunosuppressive TME.
10. The use according to claim 8 or 9, characterized in that: The cancer is breast cancer, and the cancer metastasis is lung metastasis.
Citation Information
Patent Citations
Medicine carrying lipidosome with wrapped medicines of different hydrophobic and hydrophilic properties and preparation method and application of medicine carrying lipidosome
CN107753434A
Anti-tumor pharmaceutical composition with synergistic effect, nano preparation and preparation method and application thereof
CN114469953A
Anti-tumor pharmaceutical composition and application
CN116492321A
Cited By
Pharmaceutical composition with synergistic effect for treating cancer metastasis as well as preparation method and application of pharmaceutical composition
CN120643535A
